Z-DNA binding protein 1Genealiases: C20orf183 · DAI · DLM-1 · DLM1
Q-omics provides the consensus-scored ZBP1 profile across patient tissues and cancer cell-line models. ZBP1 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ZBP1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ZBP1 protein abundance shows 18,886 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where ZBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBP1 survival associations across molecular data types. ZBP1 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBP1 RNA expression–survival associations across cancer types. High ZBP1 expression shows unfavorable associations in KIRC, UVM and LGG, but favorable associations in SKCM, HNSC and COAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ZBP1 RNA expression.
This table summarizes ZBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBP1 shows higher tumor expression in KIRC, HNSC, LUAD, STAD, BRCA and ESCA. The KIRC box plot shows higher ZBP1 RNA expression in tumor versus normal tissue (log2 FC = +0.780, t-test p < 0.001).
This table shows molecular features associated with ZBP1 in patient tissues and cancer cell lines. In patient samples, ZBP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and PANCREAS.
